Statera Biopharma

STAB · OTC

$0.0001+$0.00 (+0.00%)TodayMarket closed · Oct 20, 2:38 PM ET

Prev close $0.0001

About STAB

Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. Through its developmental Advanced Immunomodulating Multi-Component System (AIMS) platform, it has advanced several late-stage developmental product candidates. AIMS allows it to integrate multiple factors that define a superior composition, including key pharmacokinetic-pharmacodynamic relationships, potency, and selectivity. The firm has a platform of toll-like receptor (TLR) agonists with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and Entalasta. The company has clinical and preclinical programs for Crohn’s disease (STAT-201), hematology (Entolimod) and inflammation (STAT-300) in addition to potential expansion into fibromyalgia and multiple sclerosis.

Employees: 46
Headquarters: Fort Collins, Delaware
Listed: Jul 21, 2006
Sector: Health Care
Industry: Biotechnology
Website: staterabiopharma.com

Leadership

Statera Biopharma executives
Name	Title	Since	Age
Michael Handley	—	2021	51
Christopher Zosh	—	—	47
Robert Buckheit	—	—	62
Andrei Gudkov	—	—	65
Satish Chandran	—	—	67
Blake Hawley	—	—	58
John Kallassy	—	—	58
Uday Saxena	—	—	65
Nichol Ochsner	—	2022	—

Similar companies

Companies in the same industry as Statera Biopharma

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.